Press "esc" to clear
Go to Advanced Search

Showing results

110 of 468
  • Embargo expired:
    10-May-2018 4:00 PM EDT

Article ID: 693844

Study Reveals That Many Oncologists Recommend Medical Marijuana Clinically Despite Not Feeling Sufficiently Knowledgeable to Do So

Dana-Farber Cancer Institute

While a wide majority of oncologists do not feel informed enough about medical marijuana’s utility to make clinical recommendations, most do in fact conduct discussions on medical marijuana in the clinic and nearly half recommend it to their patients, say researchers who surveyed a population-based sample of medical oncologists.

Released:
1-May-2018 5:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    30-Apr-2018 11:00 AM EDT

Article ID: 693613

Genomic Analysis Unravels Complexities of the Most Common Form of Lymphoma and Enables Personalized Treatment

Dana-Farber Cancer Institute

The majority of patients with diffuse large B cell lymphoma (DLBCL) can be treated effectively. However, people whose disease recurs face a shortage of good options, especially because the disease is driven by a complicated mix of genetic alterations. Genomic analysis by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard now offers a better framework for understanding the disease’s many forms, which will help to predict individual patient outcomes and guide personalized treatment.

Released:
26-Apr-2018 5:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    27-Apr-2018 5:00 AM EDT

Article ID: 693609

In Multiple Myeloma, Different Types of Blood Biopsies Match Up Well with Bone Marrow Tests

Dana-Farber Cancer Institute

Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit. Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, however, have shown that two ways to measure multiple myeloma DNA in blood samples provide highly detailed sets of genetic information that agree well not just with each other but with results from bone marrow tests.

Released:
26-Apr-2018 4:15 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 690607

Dana-Farber’s Bank of Patient-Derived Tumor Xenografts Gets Major Boost From Novartis

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is establishing a bank of patient-derived xenograft models of more than 750 human tumors.

Released:
7-Mar-2018 5:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment
tammy-hshieh.jpg

Article ID: 690599

Cognitive Decline Prevalent Among Elderly Patients with Hematologic Cancers, Study Finds

Dana-Farber Cancer Institute

A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning

Released:
6-Mar-2018 11:05 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    11-Jan-2018 1:00 PM EST

Article ID: 687762

Discovery Suggests New Strategy for Attacking High- Profile but Elusive Target in Cancer

Dana-Farber Cancer Institute

A discovery by scientists at Dana-Farber Cancer Institute and University of Texas Southwestern Medical Center presents drug developers with an entirely new tack in targeting one of the most-wanted molecular culprits in cancer.

Released:
11-Jan-2018 1:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    4-Jan-2018 2:00 PM EST

Article ID: 687429

Mechanism for Resistance to Immunotherapy Treatment Discovered

Dana-Farber Cancer Institute

Two research groups from Dana-Farber Cancer Institute have independently discovered a genetic mechanism in cancer cells that influences whether they resist or respond to immunotherapy drugs known as checkpoint inhibitors. The scientists say the findings reveal potential new drug targets and might aid efforts to extend the benefits of immunotherapy treatment to more patients and additional types of cancer.

Released:
3-Jan-2018 2:50 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    12-Dec-2017 9:30 AM EST

Article ID: 686447

Dana-Farber/Brigham and Women’s physician wins prestigious 2017 William Dameshek Prize from the American Society of Hematology

Dana-Farber Cancer Institute

• Benjamin Ebert, MD, PhD, current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting • Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS)

Released:
7-Dec-2017 2:30 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    11-Dec-2017 5:30 PM EST

Article ID: 686443

Study Identifies Agent That Can Reverse Resistance to Targeted Drug in Some Leukemia Cell Types

Dana-Farber Cancer Institute

• Azacitidine reverses resistance to SL-401 in AML and BPDCN cell lines, researchers find • Results prompt clinical trial of SL-401 and azacitidine in AML and MDS patients

Released:
7-Dec-2017 2:30 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    10-Dec-2017 5:15 PM EST

Article ID: 686442

Study Shows Combining Chemotherapy with Targeted Drug Boosts Response in Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

Released:
7-Dec-2017 2:25 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Showing results

110 of 468





Chat now!